

Al B Benson Iii

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/232167/publications.pdf>

Version: 2024-02-01

88
papers

6,197
citations

117625

34
h-index

74163

75
g-index

92
all docs

92
docs citations

92
times ranked

8876
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. <i>Journal of Surgical Oncology</i> , 2022, 125, 560-563.	1.7	6
2	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
3	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.	1.6	68
4	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	1.6	13
5	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021, 111, 850-862.	2.5	4
6	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021, 26, 651-659.	3.7	5
7	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. <i>Advances in Oncology</i> , 2021, 1, 297-310.	0.2	0
8	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
9	Clinical trials as a path toward equity. <i>Cancer</i> , 2021, 127, 3717-3719.	4.1	0
10	Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1211-1215.	2.3	17
11	Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3165-3174.	2.5	23
12	Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.	1.1	2
13	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal/Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
14	MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 61.	4.4	13
15	Preoperative assessment of lymph node metastasis in Colon Cancer patients using machine learning: a pilot study. <i>Cancer Imaging</i> , 2020, 20, 30.	2.8	18
16	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
17	Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. <i>Oncologist</i> , 2020, 25, e808-e815.	3.7	114
18	Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. <i>Academic Radiology</i> , 2020, 28, e147-e154.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. <i>Journal of Surgical Oncology</i> , 2019, 120, 85-92.	1.7	201
20	Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. <i>Oncologist</i> , 2019, 24, 1039-e642.	3.7	16
21	TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. <i>Oncologist</i> , 2019, 24, 1446-1452.	3.7	19
22	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1066-1075.	3.7	10
23	Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1056-1065.	3.7	8
24	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	1.0	27
25	Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 849-854.	4.9	32
26	HSR19-094: A Comparison of Cancer Burden and Funding From the National Cancer Institute and Nonprofit Organizations Reveals Disparities in the Distribution of Funding Across Cancer Types. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, HSR19-094.	4.9	3
27	Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis. <i>Oncology</i> , 2018, 94, 281-288.	1.9	5
28	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. <i>Hepatology</i> , 2018, 68, 1429-1440.	7.3	174
29	Pembrolizumab for the treatment of gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1177-1187.	2.4	13
30	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018, 21, 1062-1068.	0.3	19
31	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 693-702.	4.9	289
32	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 446-464.	1.6	273
33	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017, 35, 718-726.	1.6	70
34	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
35	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1520-1526.	0.5	57
36	Epidemiology of Anal Canal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 9-15.	1.5	79

#	ARTICLE	IF	CITATIONS
37	Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 232-245.	3.8	10
38	Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World Journal of Gastroenterology, 2017, 23, 6128-6136.	3.3	8
39	Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. American Health and Drug Benefits, 2017, 10, 408-415.	0.5	12
40	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1528-1534.	4.9	17
41	<i>HER2</i> Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal of Clinical Pathology, 2016, 146, 647-669.	0.7	46
42	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. Journal of Oncology Practice, 2016, 12, 1101-1113.	2.5	25
43	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. Clinical Colorectal Cancer, 2016, 15, 37-46.	2.3	32
44	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology, 2016, 27, 1279-1287.	0.5	14
45	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2016, 151, 1155-1163.e2.	1.3	498
46	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2016, 27, 795-802.	0.5	64
47	⁹⁰Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	5.0	79
48	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. International Journal of Radiation Oncology Biology Physics, 2016, 94, 738-746.	0.8	16
49	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	4.9	181
50	Young Age and Aggressive Treatment in Colon Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 613.	7.4	18
51	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. Journal of the National Cancer Institute, 2014, 106, .	6.3	18
52	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1861-1869.	6.4	80
53	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1025-1031.	0.8	43
54	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1123-1130.	4.9	37

#	ARTICLE	IF	CITATIONS
55	Pancreatic Adenocarcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1083-1093.	4.9	307
56	S-1: another oral agent for patients with colorectal cancer. Lancet Oncology, The, 2013, 14, 1244-1245.	10.7	3
57	Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. European Journal of Cancer, 2013, 49, 3122-3130.	2.8	82
58	Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?. Annals of Translational Medicine, 2013, 1, 11.	1.7	15
59	Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 724-764.	4.9	157
60	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. Journal of Hepatology, 2012, 56, 1112-1120.	3.7	82
61	Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers. Cancer, 2012, 118, 5997-6004.	4.1	24
62	What Level of Evidence: The Elusive Balance in Drug Development. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 955-958.	4.9	0
63	Prognostic and Predictive Markers in Colorectal Cancer. Current Colorectal Cancer Reports, 2011, 7, 267.	0.5	0
64	Have the changes in treatment of rectal cancer made a significant difference to our patients?. Oncology, 2011, 25, 1323-9.	0.5	3
65	Gemcitabine remains the standard of care for pancreatic cancer. Nature Reviews Clinical Oncology, 2010, 7, 135-137.	27.6	33
66	Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer, 2009, 115, 1849-1858.	4.1	164
67	Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer. Current Colorectal Cancer Reports, 2009, 5, 151-157.	0.5	2
68	Risk assessment and adjuvant systemic therapy in resected stage II colon cancer. Current Colorectal Cancer Reports, 2009, 5, 158-165.	0.5	0
69	Cancer patient preferences for quality and length of life. Cancer, 2008, 113, 3459-3466.	4.1	159
70	ISGIO's Role in the Global Advancement of GI Oncology: Will We be Ready for the Future?. Gastrointestinal Cancer Research: GCR, 2008, 2, 1.	0.7	0
71	Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate. American Health and Drug Benefits, 2008, 1, 28-33.	0.5	4
72	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	3.7	218

#	ARTICLE	IF	CITATIONS
73	New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6913s-6920s.	7.0	31
74	Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 5-18.	2.2	112
75	New Approaches to the Adjuvant Therapy of Colon Cancer. <i>Oncologist</i> , 2006, 11, 973-980.	3.7	43
76	Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 747.	0.3	0
77	Adjuvant Chemotherapy of Stage III Colon Cancer. <i>Seminars in Oncology</i> , 2005, 32, 74-77.	2.2	27
78	Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. <i>Oncologist</i> , 2005, 10, 325-331.	3.7	37
79	Bevacizumab in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 997-1005.	3.1	52
80	The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. <i>Cancer</i> , 2003, 98, 166-175.	4.1	101
81	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. <i>Cancer</i> , 2003, 98, 484-495.	4.1	285
82	Applications of oral fluoropyrimidines in colon cancer: their role and new directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1 Suppl 3, S-17-21.	4.9	0
83	Recent and ongoing clinical trials for treating colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 871-880.	4.1	7
84	Future directions in adjuvant therapy for rectal cancer. <i>Oncology</i> , 2002, 16, 45-51.	0.5	0
85	Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N-Phosphonoacetyl-L-Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 2413-2421.	1.6	76
86	Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. , 1998, 82, 1250-1259.		171
87	Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. <i>Medical Oncology</i> , 1996, 13, 87-93.	2.5	183
88	Oltipraz: A laboratory and clinical review. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 278-291.	2.6	56